EASOTIC® Otic Suspension for Dogs
With 1 out of every 6 dogs suffering from otitis externa,1 it’s time to redesign treatment.
- OE continues to be one of the top reasons for clinic visits in the United States.2
- Recurrence can be related to not fully resolving the acute episode.
- Pet owner treatment compliance can be a major barrier to successful clinical outcomes.
- OE is a painful condition that can make pets resistant to treatment.
- Dosing with traditional drops and ointments is challenging, making it difficult for owners to comply with prescribed treatment.
Finally, an otic treatment designed to increase client compliance and help improve outcomes.
Gentle on sensitive canine ears.
Unique Airless Delivery System:
- One pump delivers an exact 1 mL dose every time.
- No messy drops to count. No more mystery.
- Precise dosing in any position.
- No more wrestling matches
One pump, once daily, for 5 days, for any size dog:
Eliminates dosing frustration.
Three Powerful Actives
- Contains Hydrocortisone Aceponate (HCA) - High topical potency comparable to betamethasone valerate3 and mometasone furoate.4
- Favorable benefit/risk ratio.3
- Rapid onset of action.
- Combined with gentamicin and miconazole.
Formulated with proven actives to fight bacteria and yeast.
Gentamicin sulfate – a proven, broad-spectrum topical antibiotic.
- Considered a first-choice antimicrobial10 – effective against a wide range of gram-positive and gram-negative aerobic bacteria.
- The safety of the topical use of gentamicin has been well established.11
Miconazole nitrate – an antifungal compound you know and trust.
- Broad-spectrum antifungal with fungistatic and fungicidal activity against
M. pachydermatis yeasts, commonly found in otitis externa.
- Low-level resistance12 and solid safety profile.13
Novel formulation is proven to work effectively in less time.
- A 5-day course with EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Suspension For Dogs is comparable to a 7-day course with other brands.
WHY IS A 1 mL DAILY DOSE IMPORTANT?
For relief of OE symptoms, it takes:
- 1 mL of medication to provide sufficient coverage of the ear canal lining, whatever the dog breed15,16
- 0.5 mL to 1 mL of treatment is needed to reach the tympanic membrane in medium- to large-sized dogs15
- Would need up to 40 drops to reach 1 mL volume
- Require treatment from 7 to 14 days
New EASOTIC Suspension quickly provides relief with:
- 1 daily dose
- Treatment for 5 days
EASOTIC Suspension is contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics. Do not use in dogs with known tympanic membrane perforation. The safe use of EASOTIC Suspension in dogs used for breeding purposes, during pregnancy, or in lactating bitches has not been evaluated.
- Banfield Pet Hospital State of Pet Health 2011 Report
- VPI Pet Insurance
- Wohlrab J, Beck GM, Neubert RHH, Suschka U, Kreft K. Hydrocortisone Aceponate activity and Benefit/Risk Ratio in relation to reference topical glucocorticoids. Skin Pharm Physiol, 2010; 23: 177-182.
- Guaguere E, et al. Clinical Practice Guidelines on the best use of topical glucocorticoids in canine dermatology. Prat Med Chir Anim Comp 2011; 46:S1-S20.
- Beiersdorf AG. UK patent application GB 2 023 145 A. Hydrocortisone derivatives, their preparation and pharmaceutical compositions containing them. Published 28 Dec 1979.
- Schafer-Korting M, Gysler A. Topical glucocorticoids with improved benefit/risk ratio. In: Korting HC, Schafer-Korting M (Eds) The benefit/risk ratio: a handbook for the rational use of potentially hazardous drugs, 1999, CRC Press, Boca Raton, p 359-372.
- Schackert C, Korting HC, Schafer-Korting M. Qualitative and quantitative assessment of the benefit/risk ratio of medium potency topical corticosteroids in vitro and in vivo. BioDrugs, 2000; 13:267-277.
- Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology. Clinical Pharmacology and therapeutic use. Am J Clin Dermatol, 2002: 3: 47-58.
- Mori M, Pimpinelli N, Giannotti B. Topical corticosteroids and unwanted local effects, improving the benefit/risk ratio. Drug Safety 1994; 10:406-412.
- Radlinsky MA and Mason DE. Diseases of the ear. In: Ettinger SJ and Felman EC. Textbook of Veterinary Internal Medicine 6th edition, Saint Louis, 2005, 1168-1186.
- Strain GM, Merchant SR, Neer M, Tedford BL. Ototoxicity assessment of gentamicin sulfate otic preparation in dogs. Am J Vet Res, 1995; 56:532-538.
- Rougier S and al. A comparative study of two antimicrobial/anti-inflammatory formulations in the treatment of canine otitis externa. Veterinary Dermatology, 2005; 16: 299-307.
- Barasch A, Griffin AV. Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. Future Microbiol., 2008; 3: 265-269.
- Data on file.
- Bloom P. Practical approach to diagnosing and managing ear disease in the dog. Michigan Veterinary Conference, 2007.
- Dickson DB, Love DN. Bacteriology of the horizontal ear canal of dogs. J Small Anim Pract, 1983; 24: 413-421.
- Boda C, Liege P, Reme C. Evaluation of Owner Compliance with Topical Treatment of Acute Otitis Externa in Dogs: A Comparative Study of Two Auricular Formulations. Intern J Appl Res Vet Med Vol 9, No 2, 2011 157-165
EASOTIC® Otic Suspension for Dogs